


Pichia pastoris Protein Expression Excellence

VTU TRACK RECORD

| Target proteins | Titer secreted [g/L] |
|--------------------------------------|----------------------|
| Albumins | up to 35 |
| hTransferrin | 11 |
| Cytokines | up to 5 |
| Fabs | up to 3 |
| GLP1-Fc (IgG4) | 2 |
| Scaffolds | 3-8 |
| dAbs | 5-15 |
| Enzymes | 5-22 |
| HSA-IFN α 2a | 16 |
| HSA-IFN α 2b | 17 |
| HSA-GCSF | 18 |
| GCSF-HSA | 20 |
| HSA-GLP-1 | 14 |
| PYY ₍₃₋₃₆₎ -HSA-GLP-1 | 13 |
| HSA-Exendin-4 | 11 |
| PYY ₍₃₋₃₆₎ -HSA-Exendin-4 | 11 |
| HSA-Chemokines | 5-12 |
| Scaffold-HSA-Fusions | 10-15 |



UNLOCK PICHIA

Pichia pastoris Protein Expression Excellence VTU ACHIEVEMENTS

Contract Research Projects

- Serving customers for 10 years
- Customers from different industry sectors
- Projects with industry giants as well as start-up companies from all continents

Licenses & Tech Transfer

- Commercial licenses granted to licensees from different industry sectors
- Successful technology transfers – Scale-up to several 1000 l (20k max)
- Clinical study material from VTU *P. pastoris* in Phase I

Advanced Technology Platform

- Proprietary *Pichia pastoris* protein expression toolbox
- Proven and globally recognized cutting-edge technology platform
- Unmatched in terms of yield, development timelines, quality & safety

Team & Facilities

- Highly skilled and experienced team
- Strong background in protein production and optimized workflows
- State of the art laboratory infrastructure and production equipment

Intellectual Property

- Key patents protecting technological leadership position
- Firm IP position, several patent families
- Freedom to operate

Development & Collaborations

- Non exclusive technology development with Boehringer Ingelheim
- Several academic collaborations
- Several B2B collaborations